Hemostatic Gauze, Chitosan-Based

This contract involves a standardization effort for Hemostatic Gauze, Chitosan-Based, intended for use across the Military Health System and various Department of Defense operational units. Only vendors listed on the Qualified Suppliers List (QSL) MW-2405-27 are eligible to participate, and they must have existing agreements with the current DoD Medical/Surgical Prime Vendors, CARDINAL HEALTH and OWENS & MINOR. The government seeks to establish a five-year Incentive Agreement with the vendor offering the lowest discounted pricing off DAPA base prices, with an anticipated selection date of December 17, 2024. The estimated annual demand for this product line is approximately $364,456.74, covering both institutional and operational needs across multiple military branches. Vendors interested in participating must submit detailed pricing, including incentive discounts, via the IA Package Worksheet, along with supporting documentation such as DAPA logs and commercial pricing data, by the specified deadline of November 21, 2024. The process emphasizes cost competitiveness, with the lowest overall price being the primary criterion for selection, although the government reserves the right to seek further discounts or revisions. The resulting Incentive Agreement is not a binding contract but aims to promote product standardization and encourage high purchase volumes, with vendors required to maintain firm pricing for 75 days and to support the government's enterprise-wide medical logistics goals.